Amarin Reports Q2 Results with Strong International Growth and Cost Savings
Amarin (NASDAQ:AMRN) reported second-quarter results showing strong international demand growth for its VASCEPA/VAZKEPA products, despite a 42% year-over-year decline in total net revenue. The drop was attributed to the absence of a $25 million licensing payment from Recordati received last year rather than weaker commercial performance. International partner sales increased by 59%, with European demand up 69% and Chinese volume rising 90%. Amarin also completed its cost savings initiative, reducing operating expenses by 38% excluding restructuring charges. The company's cash balance grew to $314.6 million from $302.6 million at the end of 2025, with positive operating cash flow for a third consecutive quarter. In the U.S., VASCEPA’s market share increased to 48%, and branded prescriptions rose by 14%. Management expects stable sales volumes in the U.S. throughout 2026 and anticipates further growth in its international partner network. Amarin remains debt-free, with a focus on expanding through partnerships while maintaining financial flexibility.